Table 2.
Agents that Target Host Factors in Development for Treatment of HBV Infection
| Compound | Mechanism and Target | Stage of Development | Sponsor | Reference |
|---|---|---|---|---|
| Myrcludex B | entry | phase 2 | Hepatera, Russia |
NCT02888106 NCT02637999 |
| GS-5801 | epidrug | phase 1 | Gilead | sponsor’s web site |
| REP 2139 | HBsAg | phase 2 | Replicor, Canada | 96, 97; NCT02565719 |
| REP 2165 | HBsAg | phase 2 | Replicor, Canada | 97; NCT02565719 |
| RO7020322 (RG7834) |
HBsAg | Terminated | Roche, Switzerland | 149; NCT02604355 |
| EYP001 | FXR agonist | phase 1 | Enyo Pharma, France | NCT03469583 |
| APG-1387 | apoptosis | phase 1 | Asscentage Pharma, China | 150; sponsor’s web site |
| Birinapant | apoptosis | terminated | TetraLogic Pharmaceutical | NCT02288208 |
| CRV431 | cyclophilin inhibitor | preclinical | ContraVir Pharmaceutical | sponsor’s web site |
| GS-9688 | TLR8 agonist | phase 2 | Gilead | NCT03491553 |
| GS-9620 | TLR7 agonist | phase 2 | Gilead, USA | NCT02579382 |
| RO6864018 (RG7795 and ANA773) |
TLR7 agonist | phase 2 | Roche, Switzerland | NCT02391805 |
| RO7020531 | TLR7 agonist | phase 1 | Roche, Switzerland | NCT02956850 |
| AL-034 | TLR7 agonist | phase 1 | Alios Biopharma | NCT03285620 |
| AIC649 | immune modulator | phase 1 | AiCuris, Germany | 151 |
| Inarigivir (GS-999 and SB 9200) |
RIGI and NOD2 agonist | phase 2 | Spring Bank |
NCT02751996 NCT03434353 |
| INO-1800 | therapeutic vaccine | phase 1 | Inovio Pharmaceuticals | NCT02431312 |
| TG1050 | therapeutic vaccine | phase 1 | Transgene, France | NCT02428400 |
| HB-110 | therapeutic vaccine | phase 1 | Genexine, South Korea |
152;NCT01641536 NCT00513968 |
| HepTcell (FP-02.2) |
therapeutic vaccine | phase 1 | Altimmune | NCT02496897 |
| JNJ-64300535 | therapeutic vaccine | phase 1 | Janssen Sciences, Belgium | NCT03463369 |
| TomegaVax HBV | therapeutic vaccine | preclinical | TomegaVax | sponsor’s web site |
| MVA-VLP-HBV | therapeutic vaccine | preclinical | GeoVax and CaroGen | sponsor’s web site |
| GS-4774 | therapeutic vaccine | terminated | Gilead | NCT02258581 |
| LTCR-H2–1 | T-cell receptor | preclinical | Lion TCR, Singapore | sponsor’s web site |
| Thymalfasin | immune modulator | phase 4 | Huashan Hospital, China | NCT03448744 |